Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male subject~* Age: 18 to 55 years (inclusive) at the time of informed consent and first dose of study medication~* Body mass index (BMI) above/equal to 18 and below/equal to 30 kg/m\^2 at Screening~* Body weight of at least 45 kg at Screening~Exclusion criteria:~* Presence or history of clinically relevant cardiovascular, central nervous system (CNS), hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash~* Known hypersensitivity to the study drugs~* Known severe allergies or significant non-allergic drug reactions~* Febrile illness within 1 week before study drug administration~* Current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs~* Subject has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Screening~* Poor peripheral venous access~* Regular use of medicines within 6 months prior to screening~* Clinically relevant findings in the electrocardiogram (ECG), physical examination or laboratory examination

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 - BAY1817080 Dose 1 (Type: EXPERIMENTAL): Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
- Group 2 - BAY1817080 Dose 2 (Type: EXPERIMENTAL): Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg \[13C715N\]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
- Group 3 - BAY1817080 Dose 3 (Type: EXPERIMENTAL): Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence

Based on this trial design, predict the completion outcome and termination type (if applicable).